Skip to main content
Equibles
LGVN logo

LGVN · Longeveron Inc.

Track LGVN — free

Use LGVN with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about LGVN

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.74 +0.04 (+6.06%) At close · Aug 14
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company has prepared a cash flow forecast which indicates that it does not have sufficient cash to meet its minimum expenditure commitments for one year from the date these financial statements are available to be issued and therefore needs to raise additional funds to continue as a going concern. As a result, there is substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 12, 2026
Market Cap
$23.59M
Shares
31.88M

Longeveron Inc. Earnings Call Transcripts

Every quarterly earnings call for Longeveron Inc. (LGVN) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲14.2% $265,000 −$5.24M '22 Q3 22-11-14 ▼42.1% $121,000 −$4.46M '22 Q4 23-03-10 ▼24.6% $279,000 −$4.65M '23 Q1 23-05-12 ▼53.4% $217,000 −$5.63M '23 Q2 23-06-30 ▼43.4% $150,000 −$5.11M '23 Q3 23-11-10 ▼47.9% $63,000 −$6.03M '23 Q4 24-02-27 ▲96.4% $548,000 −$4.06M '24 Q1 24-05-14 ▲115.7% $468,000 −$3.41M '24 Q2 24-08-14 ▲415.3% $773,000 −$4.42M '24 Q3 24-11-12 ▲857.1% $603,000 −$4.08M '24 Q4 25-02-28 ▼30.5% $381,000 −$5.01M '25 Q1 25-05-08 ▼32.5% $316,000 −$5.03M '25 Q2 25-08-13 ▼82.3% $137,000 −$7.22M '25 Q3 25-11-04 ▼39.5% $365,000 −$5.44M '25 Q4 25-12-31 ▲4.5% $398,000 −$4.74M '26 Q1 26-05-13 LATEST ▼9.2% $287,000 −$6.07M '26 Q2 26-08-12
Earnings call
FY26 · Q2
2026-08-12
Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026
Confident tone Regulatory pathway and FDA engagement ELPIS-2 HLHS Phase 2B data readout External validation and XPRIZE recognition
Revenue
$287,000
▼ 9.2% YoY
Diluted EPS
$-0.19
Gross margin
63.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-13
Longeveron Inc. Q1 FY2026 Earnings Call
Positive tone PDCM program progression ELPIS-2 HLHS readout Pipeline breadth beyond HLHS
Revenue
$398,000
▲ 4.5% YoY
Diluted EPS
$-0.19
Gross margin
66.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2025-12-31
Longeveron Inc. Q4 FY2025 Earnings Call
Confident tone ELPIS II HLHS Pivotal Trial Pediatric Dilated Cardiomyopathy (PDCM) Priority Review Voucher (PRV)
Revenue
$365,000*
▼ 39.5% YoY
Gross margin
70.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Longeveron Inc. Q3 FY2025 Earnings Call
Balanced tone BLA preparedness and timeline slip ELPIS-2 / HLHS pivotal trial Pipeline breadth and other indications
Revenue
$137,000
▼ 82.3% YoY
Diluted EPS
$-0.39
Gross margin
91.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-13
Longeveron Inc. Q2 FY2025 Earnings Call
Confident tone iPSC technology platform / differentiation Pediatric dilated cardiomyopathy pipeline expansion Alzheimer's disease program and partnership strategy
Revenue
$316,000
▼ 32.5% YoY
Diluted EPS
$-0.33
Gross margin
46.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Longeveron Inc. Q1 FY2025 Earnings Call
Revenue
$381,000
▼ 30.5% YoY
Diluted EPS
$-0.34
Gross margin
72.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-28
Longeveron Inc. Q4 FY2024 Earnings Call
Confident tone HLHS (Hypoplastic Left Heart Syndrome) Program Alzheimer's Disease Program Laromestrocel / Lomecel-B Naming and Pipeline
Revenue
$603,000*
▲ 857.1% YoY
Gross margin
87.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Longeveron Inc. Q3 FY2024 Earnings Call
Confident tone HLHS / ELPIS II pivotal trial Alzheimer's disease program (CLEAR MIND) ELPIS I long-term follow-up data
Revenue
$773,000
▲ 415.3% YoY
Diluted EPS
$-0.34
Gross margin
88.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-14
Longeveron Inc. Q2 FY2024 Earnings Call
Confident tone Pipeline and future strategy (Longeveron 2.0) HLHS (Hypoplastic Left Heart Syndrome) program Alzheimer's disease program
Revenue
$468,000
▲ 115.7% YoY
Diluted EPS
$-1.83
Gross margin
73.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-14
Longeveron Inc. Q1 FY2024 Earnings Call
Confident tone Alzheimer's Disease Program Upcoming Catalysts and Pipeline HLHS Program (ELPIS II)
Revenue
$548,000
▲ 96.4% YoY
Diluted EPS
$-1.61
Gross margin
60.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-27
Longeveron Inc. Q4 FY2023 Earnings Call
Confident tone HLHS / ELPIS Program Lead Priority Alzheimer's / CLEAR MIND Trial ELPAS II Enrollment Progress and Plans
Revenue
$63,000*
▼ 47.9% YoY
Gross margin
-3.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-10
Longeveron Inc. Q3 FY2023 Earnings Call
Revenue
$150,000
▼ 43.4% YoY
Diluted EPS
$-2.79
Gross margin
36.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-06-30
Longeveron Inc. Q2 FY2023 Earnings Call
Revenue
$217,000
▼ 53.4% YoY
Diluted EPS
$-2.67
Gross margin
42.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-12
Longeveron Inc. Q1 FY2023 Earnings Call
Revenue
$279,000
▼ 24.6% YoY
Diluted EPS
$-2.21
Gross margin
27.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-10
Longeveron Inc. Q4 FY2022 Earnings Call
Revenue
$121,000*
▼ 42.1% YoY
Gross margin
66.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-14
Longeveron Inc. Q3 FY2022 Earnings Call
Revenue
$265,000
▲ 14.2% YoY
Diluted EPS
$-2.50
Gross margin
34.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-12
Longeveron Inc. Q2 FY2022 Earnings Call
Revenue
$466,000
▼ 4.7% YoY
Diluted EPS
$-2.70
Gross margin
34.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-13
Longeveron Inc. Q1 FY2022 Earnings Call
Revenue
$370,000
▼ 1.6% YoY
Diluted EPS
$-1.70
Gross margin
44.6%
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-11
Longeveron Inc. Q4 FY2021 Earnings Call
Revenue
$209,000*
▼ 82.3% YoY
Gross margin
33.0%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-12
Longeveron Inc. Q3 FY2021 Earnings Call
Revenue
$232,000
▼ 87.6% YoY
Diluted EPS
$-2.50
Gross margin
70.7%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-13
Longeveron Inc. Q2 FY2021 Earnings Call
Revenue
$489,000
▼ 44.2% YoY
Diluted EPS
$-2.60
Gross margin
42.5%
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-14
Longeveron Inc. Q1 FY2021 Earnings Call
Revenue
$376,000
▼ 78% YoY
Gross margin
39.6%
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-30
Longeveron Inc. Q4 FY2020 Earnings Call
Revenue
$1.18M*
Gross margin
44.8%
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–23 of 23 earnings calls
Key facts CIK 1721484 CUSIP 54303L203 13F (30d) 36 filings 36 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)